2026-01-14 19:49:51

ImmunityBio Advances Lung Cancer Treatment Pipeline

Biotech innovator ImmunityBio has unveiled a significant breakthrough in its oncology division, marking substantial progress in its lung cancer treatment research. The development reinforces the platform's commitment to leveraging immunotherapy approaches for critical disease indications.

This milestone demonstrates how emerging biotech players are integrating advanced research capabilities into the Web3 ecosystem, potentially opening new avenues for tokenized healthcare innovation and community-driven drug development models. The progress could attract institutional interest and reshape how investors view crypto-native biotech initiatives.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

5 Likes

Reward
5
7
Repost
Share

Comment

0/400

DAOdreamer

· 6h ago

Web3 biotechnology is making new moves again, but how long this hot topic can last depends on subsequent clinical data.

View OriginalReply0

PancakeFlippa

· 11h ago

There are new developments in lung cancer treatment, and immunotherapy is definitely worth paying attention to. The Web3 biotech track still seems to have opportunities, but whether it can truly be implemented depends on the actual progress. Tokenized healthcare? Is that really reliable? It always feels a bit mysterious when biotech and the crypto world combine. ImmunityBio's recent progress is good, but the key is when it can reach clinical trials. Immunotherapy + Web3 + community-driven... sounds very exciting, but what about in practice?

View OriginalReply0

Liquidated_Larry

· 11h ago

Immunotherapy is coming out with another set? Honestly, I'm a bit tired of this direction... But if they can really develop something, the combination of biotech + Web3 definitely has some potential.

View OriginalReply0

MEVHunter

· 11h ago

ngl the "tokenized healthcare" angle here screams classic retail copium... where's the actual mempool data showing institutional accumulation? until i see the arbitrage spread widening on their governance token, this is just another hype narrative with zero alpha

Reply0

Token_Sherpa

· 11h ago

ngl, "crypto-native biotech" is just tradfi cope with blockchain lipstick. where's the actual token utility beyond pumping?

Reply0

AltcoinHunter

· 11h ago

Lung cancer immunotherapy is back? This time it's really different... tokenized healthcare sounds fancy, but whether it can actually deliver depends on future data, don't want another PPT revolution --- ImmunityBio this time really has something, the hundredfold opportunity in crypto biotech is right in front of us, the key is whether retail investors can wait for that day --- From a technical perspective, this project is in the bottoming phase, but honestly I'm more concerned about the funding progress... whether to get on board depends on the institutional side --- Another Web3 biotech, retail investors, don't rush to go all-in, we've seen this story before [laugh cry] --- Immunotherapy + blockchain combo, either a big hit or a big flop, no middle ground, I bet it will succeed --- Wait, what does lung cancer treatment breakthrough have to do with crypto price fluctuations? Or is this just a reflection of the rising consensus value? --- It looks like a potential new star, but after cutting losses, what I fear most is watching others take off... never mind, I won't watch anymore

View OriginalReply0

not_your_keys